- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Not listed
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 89
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
- Conditions
- Hereditary Angioedema
- Interventions
- STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • San Diego, California • Santa Monica, California + 3 more
- Conditions
- Hereditary Angioedema
- Interventions
- STAR-0215
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 9 more
- Conditions
- Hereditary Angioedema
- Interventions
- Icatibant
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more
- Conditions
- Hereditary Angioedema
- Interventions
- Ruconest
- Biological
- Lead sponsor
- Bernstein Clinical Research Center
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Cincinnati, Ohio
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- navenibart, Placebo
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
- Conditions
- Hereditary Angioedema
- Interventions
- C1 esterase inhibitor [human] (C1INH-nf)
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Bentonville, Arkansas • Los Angeles, California + 27 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 42
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
- Conditions
- CVI - Common Variable Immunodeficiency
- Interventions
- C1-esterase inhibitor [recombinant] (C1-INH-R)
- Biological
- Lead sponsor
- IMMUNOe Research Centers
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Centennial, Colorado
- Conditions
- Hereditary Angioedema (HAE), Angioedema
- Interventions
- Lanadelumab 150 mg, Lanadelumab 300 mg
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 8
- States / cities
- Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hereditary Angioedema
- Interventions
- C1 Esterase Inhibitor
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 13
- States / cities
- Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 99 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 600 mg, Drug: KVD900 300 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
- Conditions
- Kidney Transplant
- Interventions
- Berinert, Placebo for Berinert
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more
- Conditions
- Hereditary Angioedema
- Interventions
- CSL312, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
- Conditions
- Angioedema, Hereditary, Types I and II
- Interventions
- KVD824, Placebo to KVD824
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more